{"id":"NCT01040780","sponsor":"Betta Pharmaceuticals Co., Ltd.","briefTitle":"Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients","officialTitle":"A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-03","completion":"2011-12","firstPosted":"2009-12-30","resultsPosted":"2012-05-24","lastUpdate":"2014-02-14"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Icotinib","otherNames":["BPI-2009","Conmana"]},{"type":"DRUG","name":"Gefitinib","otherNames":["ZD1839","Iressa"]}],"arms":[{"label":"Icotinib","type":"EXPERIMENTAL"},{"label":"Gefitinib","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"2-7 months","effectByArm":[{"arm":"Icotinib","deltaMin":4.6,"sd":null},{"arm":"Gefitinib","deltaMin":3.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["China"]},"refs":{"pmids":["23948350","21144613","23948351","22112293"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":200},"commonTop":["Rash","Diarrhea","Pain","Aminotransferase Increased","Cough"]}}